PROSTATE CANCER. A MULTIDISCIPLINARY APPROACH TO DIAGNOSIS AND MANAGEMENT

• I. Epidemiology, Screening, and Diagnosis
1 Introduction: The Multidisciplinary Approach to Prostate Cancer
2.1 Epidemiology of Prostate Cancer
2.2 Diet and Prostate Cancer
2.3 Epidemiology: Obesity as a Risk Factor
3.1.1 Screening and Diagnosis: The Pros of PSA Screening
3.1.2 The Argument Against Prostate Cancer Screening
3.1.3 How Do We Improve PSA Accuracy?
3.2 Screening and Diagnosis: An Update on the ISUP-Modified Gleason Score and Its Controversies
3.3 Evaluation of Distant Disease: The Utility of Nuclear Imaging
4 Current Approaches to Prostate Cancer Staging and Risk Stratification: In the Midst of a Paradigm Shift
5.1 Novel Molecular and Genotype Profiling in Prostate Cancer: The Future of Screening, Diagnosis, and Staging
5.2 Genomics and Risk Assessment
5.3 Future Direction: Novel Urine and Serum Markers
5.4 Morphometric and Systems Pathology: The Future of Screening, Diagnosis, and Staging
5.5.1 PET: The Future of Screening, Diagnosis, and Staging for Prostate Cancer
5.5.2 DCE MRI and MR Spectroscopy: The Future of Screening, Diagnosis, and Staging
5.5.3 Future Direction: Contrast Ultrasound 109
6 Counseling Patients With Clinically Localized, High-Risk Prostate Cancer
• II. Treatment for Low-Risk, Localized Disease
7 Active Surveillance for Prostate Cancer: An Overview
8 Treatment of Low-Risk, Localized Prostate Cancer: A Holistic Approach With Diet
9.1 Traditional Radical Prostatectomy
9.2 Laparoscopic Radical Prostatectomy: Techniques and Complications
9.3 Robotic Radical Prostatectomy: The Thomas Jefferson University Experience
9.4 Surgical Training, Digital Capture, Virtual Reality, and the Future of Radical Prostatectomy
10.1.1 External Beam Radiation Therapy: Conventional Fractionation
10.1.2 Hypofractionated Radiation Therapy for Localized Prostate Cancer
10.1.4 Treatment of Low-Risk, Localized Prostate Cancer: Use of Proton Therapy
10.2 Treatment of Low-Risk, Localized Prostate Cancer: Brachytherapy
11.1 Treatment of Low-Risk, Localized Prostate Cancer: General Principles of Ablative and Focal Therapies
11.2 Hyperthermia for Prostate Cancer
11.3 Ablative Techniques: Vascular Targeted Photodynamic Therapy
11.4 Laser Ablative Techniques for Prostate Cancer
12.1 Quality of Life With Surgery
12.2 Quality of Life With Androgen Deprivation Therapy
12.3 Quality of Life With External Beam Radiation Therapy
12.4 Quality of Life With Brachytherapy for Low-Risk Localized Prostate Cancer
13 Role for Comparative Effectiveness Research in Treatment Decision Making
14 Defining Treatment Failure for Localized Prostate Cancer: PSA and Beyond
15 Prognosis After Biochemical Failure and Surrogate Endpoints for Prostate Cancer–Specific Mortality
• III. Treatment for High-Risk, Localized, and Locally Advanced Disease
16 Treatment of High-Risk Prostate Cancer: The Role of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy
• IV. Treatment of Disseminated Disease
17 Salvage Therapy for Rising PSA
18 Metastatic Hormone Sensitive Prostate Cancer
19.1 Metastatic Castrate-Resistant Prostate Cancer: Mechanisms of Hormone Escape
19.2 Metastatic Castrate-Resistant Prostate Cancer: Role of Chemotherapy and Multifaceted Treatment Paradigms
19.3 Metastatic Castrate-Resistant Prostate Cancer: Role of Androgen Signaling Inhibitors
19.4.1 Radiation and the Immune System
19.4.2 Immunotherapy: Agents Targeting Prostate Cancer
19.5 Treatment of Bony Metastases: Inhibitors of Bone Resorption
19.6 Treatment of Bone Metastases: Radiopharmaceuticals
19.7 Prognostication of Metastatic Castration-Resistant Prostate Cancer
Index

With an emphasis on multidisciplinary collaboration and decision-making, this practical resource reflects the extraordinary advances in the treatment of prostate cancer during the past five years. Approximately thirty international, leading-edge investigators describe the most current evidence-based approaches to prostate cancer treatment. The book provides a comprehensive view of the entire spectrum of prostate cancer management from initial screening through novel and experimental treatments that have the potential for a major impact on practice.

The book first reviews fundamental issues including epidemiology, screening, risk reduction, diagnosis and pathologic characterization, staging, and imaging. This includes strategies for improving the accuracy of PSA screening and an update on controversies surrounding the ISUP Modified Gleason Score. The book covers novel molecular and genotype profiling in prostate cancer, including morphometric and systems pathology. Detailed information is provided on radiographic imaging for diagnosis and staging. The treatment sections of the book correspond to the staging of disease. The treatment of localized disease addresses the range of multidisciplinary management options including a discussion of prostate cancer's impact on the quality of life.

A detailed review of multimodal therapies (medical, surgical, and radiologic) addresses the treatment of localized advanced disease, and coverage of advanced metastatic prostate cancer reviews current management options including a range of promising novel and experimental agents. The book also discusses counseling the high-risk patient. Several chapters incorporate models of care delivery, patient navigation for multidisciplinary care, genomic and risk assessment, and comparative effects of research in treatment decision-making. The book is designed as a management text for all health care professionals who provide care for prostate cancer patients as well as patients, families, and advocates. Extensive references offer opportunities for additional study.

Key Features:
• Delineates a practical, concise approach to multidisciplinary management of prostate cancer
• Provides a wide range of perspectives and expertise
• Written and edited by an international, multidisciplinary team of prostate cancer specialists
• Focuses on such key issues as special populations, screening controversies, patient counseling, and quality of life
• Includes discussion of important emerging topics such as gene profiling and targeted therapies and comparative effectiveness data

Contents
• Epidemiology, Screening, and Diagnosis
• II. Treatment for Low-Risk, Localized Disease
• III. Treatment for High-Risk, Localized, and Locally Advanced Disease
• IV. Treatment of Disseminated Disease
Index